Stock Picks Today: HDFC Bank, BSE, Sun Pharma, SBI Life, HDFC Life And More On Brokerage's Radar
NiveshIQ
NSE: SUNPHARMA · Pharma
Sun Pharmaceutical Industries Ltd.
₹1,840.00▼ ₹21.00 (-1.13%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SUNPHARMA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Limited is a leading generic pharmaceutical company with a diverse portfolio of branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company's key revenue drivers include its generic formulations, specialty medications, and APIs for various therapeutic areas. Recent developments include a 10.46% year-over-year increase in consolidated net sales to Rs 15,299.88 crore in June 2026, and a 27% rise in Q1 net to ₹2,895 crore. The company has also been expanding its premium offerings to cushion the impact of US generics pain. Sun Pharma's competitive position is strengthened by its strong presence in the Indian and US markets, as well as its partnerships with leading pharmaceutical compa
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹48,497 Cr +10.50% | ₹52,578 Cr +8.40% | ₹58,462 Cr +11.20% |
| EBITDA Margin | 26.85% | 29.05% | 33.70% |
| Net Profit | ₹9,611 Cr +12.90% | ₹10,965 Cr +14.10% | ₹12,872 Cr +17.40% |
| EPS | ₹39.91 | ₹45.55 | ₹47.80 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Sun Pharma Subsidiaries Settle US Generic Drug Pricing Antitrust Litigation For Confidential Amount
Sun Pharma Subsidiaries Settle US Generic Drug Pricing Antitrust Litigation For Confidential Amount
🔒
+ 3 more stories about Sun Pharmaceutical Industries Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹15, 300 Cr, PAT ₹2, 901 Cr, EPS ₹12.10, EBITDA margin 33.6%. Growth context: revenue QoQ +4.7%, PAT QoQ +7.1%. Street verdict: inline, revenue surprise -1.1%, PAT surprise -3.1%.
Management's near-term growth strategy hinges on product launches, approvals, and therapy-mix improvement, which are exp...
FY26 (last completed FY): revenue ₹58, 462 Cr, PAT ₹12, 872 Cr, EBITDA margin 33.7%, EPS ₹47.80. Year-on-year: revenue Y...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SUNPHARMA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SUNPHARMA alongside your other holdings
Unlock full SUNPHARMA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Sun Pharmaceutical Industries Ltd.?
NiveshIQ detects active intelligence signals for Sun Pharmaceutical Industries Ltd. (SUNPHARMA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Sun Pharmaceutical Industries Ltd.?
Sun Pharmaceutical Industries Ltd. operates in the Pharma sector with a market capitalisation of ₹47,122,937.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.